(HealthDay News) – Oral fluoroquinolone use is not associated with the risk of retinal detachment, according to a Danish cohort study published in the Nov. 27 issue of the Journal of the American Medical Association.

Björn Pasternak, MD, PhD, from the Statens Serum Institut in Copenhagen, Denmark, and colleagues conducted a nationwide, register-based cohort study in Denmark to examine whether oral fluoroquinolone use is associated with an increased risk of retinal detachment. The cohort included 748,792 episodes of fluoroquinolone use and 5,520,446 control episodes of nonuse.

The researchers identified 566 cases of retinal detachment, of which 82% were rhegmatogenous detachments. Seventy-two cases occurred in fluoroquinolone users, while 494 occurred in control nonusers. The risk of retinal detachment was not significantly increased with fluoroquinolone use compared to nonuse, with adjusted relative risks of 1.29 (95% confidence interval [CI], 0.53–3.13) for current use; 0.97 (95% CI, 0.46–2.05) for recent use; 1.37 (95% CI, 0.80–2.35) for past use; and 1.27 (95% CI, 0.93–1.75) for distant use. For current use, the absolute risk difference, estimated as the adjusted number of retinal detachment cases per 1,00,00 treatment episodes, was 1.5 (95% CI,−2.4–11.1).

“In this cohort study based on the general Danish population, oral fluoroquinolone use was not associated with increased risk of retinal detachment,” the authors write.

Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)